A chemical biology approach to identifying cyclic peptide antibiotics

南安普顿大学将专注于将SICLOPPS技术应用于抗菌和抗真菌靶标，最初的重点是大肠杆菌。默克公司和南安普顿大学将就感兴趣的细胞类型(S)和表型读数(S)达成一致，以支持这一战略。南安普顿大学随后将应用SICLOPPS技术来预先讨论细胞类型，并检查感兴趣的表型(S)的结果。南安普顿大学将进行数据解释、随后的生物靶标鉴定和多肽合成/优化。如果合适，默克公司将提供多肽合成支持。默克公司将在适当的基于细胞的分析或无细胞分析中测试由南安普顿大学鉴定的最终多肽，并提供与生物靶标去卷积相关的适当化学生物学支持。最低限度，成功的定义是鉴定出对感兴趣的细菌具有适度体外抗菌活性的新的多肽化学物质。

University of Southampton will focus on applying the SICLOPPS technology to antibacterial and antifungal targets, with initial focus on E. coli. Merck and University of Southampton will agree upon cell type(s) and phenotypic read-out(s) of interest to support this strategy. University of Southampton will then apply SICLOPPS technology to pre-discussed cell-types and examine results for phenotype(s) of interest. Data interpretation, subsequent biological target identification, and peptide synthesis/optimization will be performed at University of Southampton. If appropriate, Merck will provide peptide synthesis support.Merck will test resulting peptides identified by University of Southampton in appropriate cell-based assays or cell-free assays and provide appropriate chemical biology support as it relates to biological target deconvolution. Minimally, success is defined as identification of new peptidic chemical matter with modest in vitro antimicrobial activity against the bacteria of interest.